Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Biological: REGN728
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01197391
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT01187563
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: REGN727(SAR236553)
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01161082
- Locations
- 🇺🇸
Site 1, Cincinnati, Ohio, United States
🇺🇸Site 2, Knoxville, Tennessee, United States
Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01074372
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: REGN88
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01055899
Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT01053702
A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01026519
- Locations
- 🇷🇺
Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow, Russian Federation
Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01026597
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Biological: REGN668
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01015027
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: REGN88
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01011959